- Franken M. D., van Rooijen E. M., May A. M., Koffijberg H., van Tinteren H., Mol L., ten Tije A. J., Creemers G. J., van der Velden A. M. T., Tanis B. C., Uyl-de Groot C. A., Punt C. J. A., Koopman M., van Oijen M. G. H. Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer European journal of cancer (Oxford, England 2017;75:204-212 [PubMed]
- ter Veer Emil, van Oijen Martijn G. H., van Laarhoven Hanneke W. M. S-1 with leucovorin and oxaliplatin for advanced gastric cancer lancet oncology 2016;17 (2):E41 [PubMed]
- ter Veer Emil, Haj Mohammad Nadia, van Valkenhoef Gert, Ngai Lok Lam, Mali Rosa M. A., Anderegg Maarten C., van Oijen Martijn G. H., van Laarhoven Hanneke W. M. The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis Journal of the National Cancer Institute 2016;108 (10):djw166 [PubMed]
- Belderbos Tim D. G., van Oijen Martijn G. H., Moons Leon M. G., Siersema Peter D. The "golden retriever" study: improving polyp retrieval rates by providing education and competitive feedback Gastrointestinal endoscopy 2016;83 (3):596-601 [PubMed]
- Bromley Erica G., May Folasade P., Federer Lisa, Spiegel Brennan M. R., van Oijen Martijn G. H. Explaining persistent under-use of colonoscopic cancer screening in African Americans: A systematic review Preventive medicine 2015;71:40-48 [PubMed]
Martijn van Oijen PhD is Evaluation of Cancer Care programleader of the Cancer Center Amsterdam. He is a principal investigator appointed as Associate Professor at the department of Medical Oncology at the Academic Medical Center (AMC), Amsterdam. Concurrently, he serves as methodology consultant for IKNL, and is a member of the scientific committee of PALGA.
He studied biomedical sciences with two majors -epidemiology and health technology assessment- and obtained his PhD at the Radboud University Medical Center. Dr. van Oijen has worked as an Assistant Professor at UMC Utrecht and as Associate Professor and Associate Director of the Quality Initiative at the University of California Los Angeles (UCLA).
PhD M.G.H. van Oijen (Evaluation of Cancer Care)
Dr. van Oijen's research group focuses on improving the quality of cancer care by forming and analyzing large datasets, combined with state of the art information technology, including decision support tools and wearable technology. His research can be described in three research topics:
Quality of care
Data from large existing available datasets, such as the Dutch Cancer Registry or the nationwide pathology database PALGA, are studied for treatment patterns, guideline adherence and health outcomes using state of the art statistical methodology. His group is highly involved in linking these datasets and the process of enrichment with patient-reported outcomes and biomaterial for gastrointestinal cancer in the 3P-projects (PACAP, POCOP and PLCRC)
This research focuses on translation from results of clinical trials and cohort studies towards implementation in clinical practice. Using Bayesian network meta-analyses, and cost-effectiveness research, input for digital decision support tools is generated. These tools, e.g. IBM Watson for Oncology, are then evaluated in clinical practice in a framework for optimal cancer care.
Cancer care is mostly focused on in-hospital contacts and services, but most events occur out-of-hospital. Using wearable technology, objective, passively collected, information becomes available about the patient journey. When properly interpreted with user-friendly dashboards, this can result in value-based cancer care.
MD T.D. Belderbos
BA M.K. Bos
Prof. MD PhD C.J.A. Punt (Clinical and translational research in gastrointestinal cancer, with focus on colorectal cancer)
- Bristol-Myers Squibb B.V. (0059)